What is the Secret Behind Beauty Health Company’s Skyrocketing Performance? Is it Time to Jump on The Investment Train?

Photo of author
Written By Kevin MacDonald

BeautyHealth Company (NASDAQ: SKIN), renowned for its flagship brand Hydrafacial, has disclosed its financial performance for the full year and fourth quarter ended December 31, 2023. 

Despite facing challenges in certain regions, the company achieved significant milestones, with full-year net sales reaching $398 million, reflecting an 8.8% increase over the previous year. 

However, fourth-quarter net sales declined slightly to $96.8 million, primarily attributed to lower equipment sales in the Americas. 

This analysis will delve into the financial highlights, operational metrics, and strategic outlook provided by BeautyHealth, shedding light on its performance and future prospects.

Financial Highlights

The fourth quarter of 2023 saw net sales of $96.8 million, reflecting a marginal decrease of (1.3)% compared to the prior year period. 

Challenges in the Americas were offset by growth in Asia-Pacific (APAC) and Europe, the Middle East, and Africa (EMEA) regions.

Gross margin for Q4 2023 stood at 47.2%, down from 67.8% in Q4 2022, primarily impacted by higher inventory-related charges and product costs. The adjusted gross margin also declined to 54.6% from 73.6% in the previous year.

Credit: DepositPhotos

The Net loss amounted to $(9.4) million in Q4 2023, in contrast to net income of $6.5 million in Q4 2022, primarily due to gross margin pressures.

The adjusted EBITDA for Q4 2023 was $3.4 million, down from $17.6 million in Q4 2022, largely driven by gross margin pressures.

Overall, the full 2023 net sales increased by 8.8% to $398.0 million, driven by growth in APAC and EMEA regions.

The gross margin for FY 2023 declined to 39.0% from 68.0% in FY 2022, mainly due to inventory write-downs and charges associated with the Syndeo Program, higher inventory-related charges, and product costs.

The net loss for FY 2023 amounted to $(100.1) million compared to net income of $44.2 million in FY 2022, primarily due to gross margin pressures.

Read More: Sunnova Energy’s Entanglement in Grueling Battle Over Loan Agreement Continues 

Operational Metrics

During Q4 2023, the company placed 1,551 delivery systems, down from 2,067 in the prior year period, with challenges in the Americas partially offset by growth in APAC.

For FY 2023, BeautyHealth placed 8,287 delivery systems, slightly lower than the prior year, primarily due to challenges in the Americas.

Strategic Outlook

Despite facing operational challenges, BeautyHealth remains confident in its underlying strengths, including a clinically proven treatment, a passionate provider community, unique partner portfolio, and growing addressable market.

The company is focused on tapping into the still-untapped global opportunity and advancing its market presence.

Also Read: A Deep Dive Into Cardiff Oncology’s Clinical Progress 

Financial Guidance

As of March 2024, BeautyHealth provided financial guidance for the first quarter and fiscal year 2024. The company expects net sales for Q1 2024 to range between $77 million and $83 million, with an adjusted EBITDA of ($6) million to ($9) million. 

For fiscal year 2024, BeautyHealth anticipates flat to low-single-digit percentage growth in net sales and an adjusted EBITDA exceeding $40 million.

Financial Performance Shows Mixed Results 

BeautyHealth’s financial performance for the full year and fourth quarter of 2023 reflects a mixed outcome, with growth in international markets partially offsetting challenges in the Americas. 

Credit: DepositPhotos

Despite facing gross margin pressures, the company remains optimistic about its long-term prospects and is committed to driving growth through strategic initiatives and market expansion efforts. 

The provided financial guidance for 2024 demonstrates BeautyHealth’s resilience and determination to navigate through evolving market dynamics while delivering long-term value to shareholders and stakeholders.

Read Next: ACCO Brands: An Undervalued Player in the Consumer and Business Products Sector


You should read and understand this disclaimer in its entirety before joining or viewing the website or email/blog list of SmallCapStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.

The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.

The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.

By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: www.SmallCapStocks.com/Disclaimer and www.SmallCapStocks.com/Privacy-Policy

By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.